Coherus BioSciences Inc - Asset Resilience Ratio
Coherus BioSciences Inc (CHRS) has an Asset Resilience Ratio of 11.71% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Coherus BioSciences Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Coherus BioSciences Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Coherus BioSciences Inc.
Liquid Assets Composition Over Time
This chart breaks down Coherus BioSciences Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read CHRS current and long-term liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $22.38 Million | 11.71% |
| Total Liquid Assets | $22.38 Million | 11.71% |
Asset Resilience Insights
- Moderate Liquidity: Coherus BioSciences Inc has 11.71% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Coherus BioSciences Inc Industry Peers by Asset Resilience Ratio
Compare Coherus BioSciences Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Coherus BioSciences Inc (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Coherus BioSciences Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.22% | $83.25 Million | $258.34 Million | -- |
| 2024-12-31 | 0.00% | $0.00 | $448.53 Million | -- |
| 2023-12-31 | 2.36% | $14.86 Million | $629.60 Million | -24.29pp |
| 2022-12-31 | 26.65% | $128.13 Million | $480.85 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $679.33 Million | -- |
| 2017-12-31 | 0.04% | $60.00K | $162.61 Million | +0.00pp |
| 2016-12-31 | 0.03% | $60.00K | $178.49 Million | +0.01pp |
| 2015-12-31 | 0.03% | $60.00K | $212.38 Million | 0.00pp |
| 2014-12-31 | 0.03% | $60.00K | $187.22 Million | -0.07pp |
| 2013-12-31 | 0.11% | $50.00K | $47.45 Million | -0.08pp |
| 2012-12-31 | 0.19% | $50.00K | $26.53 Million | -- |
About Coherus BioSciences Inc
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin… Read more